2025-01-16 16:55:10
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China
Health/ 2023-07-22
TransThera Announces that the IND Applic...

NANJING,China,Feb. 18,2022-- TransThera Sciences (Nanjing),Inc. ("TransThera") announced that the U.S. Food and Drug Administratio...

Keymed Bio Joins Hang Seng Family of Indexes
Corporate/ 2023-07-24
Keymed Bio Joins Hang Seng Family of Ind...

HONG KONG,Feb. 18,2022--According to the quarterly review results of Hang Seng Family of Indexes,Keymed Biosciences Inc. (2162. HK) was incl...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release